Prostate Cancer BCR Risk Lower With Neoadjuvant Docetaxel, ADT

The role of neoadjuvant chemohormonal therapy in surgically treated high-risk prostate cancer has been controversial. A trial compared the addition of neoadjuvant docetaxel chemo to hormonal therapy alone and prostate cancer biochemical recurrence risk.

Related Keywords

Renji ,Henan ,China ,Shanghai ,Boston ,Massachusetts ,United States ,Adams Kibel ,Jiahua Pan ,Shanghai Jiao Tong University , ,Renji Hospital ,